The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment
Open accessAbstract
Hyperlipidemia so commonly complicates heavy proteinuria that it has come to be regarded as an integral feature of the nephrotic syndrome (NS). Characteristically, total plasma cholesterol and triglyceride levels are elevated, as are very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol. Although high-density lipoprotein (HDL) concentrations may be normal, HDL subtypes are abnormally distributed, with a reduction of HDL2 and an increase in HDL3. In addition, lipoprotein (a) [Lp (a)] levels may be elevated. The mechanisms underlying these abnormalities are multifactorial, involving both increased rates of lipoprotein synthesis and defective clearance and catabolism of circulating particles. Although recent dietary and therapeutic studies have demonstrated that nephrotic hyperlipidemia can be effectively treated, the need for such intervention has not been clearly established. This pattern of lipoprotein abnormality is associated with an increased risk of cardiovascular disease in the general population, and several studies have suggested that nephrotic individuals are more likely to develop atherosclerosis. However, no prospective trials have evaluated the relationship between deranged lipid metabolism and coronary or cerebral artery disease in patients with NS. In addition, although recent experimental studies suggest that lipid abnormalities may accelerate renal injury and that lipid-lowering agents may protect renal function, there is little current evidence to suggest that such intervention is of value in preserving residual renal function in humans. Further studies are clearly required to assess the potential long-term benefits of lipid-lowering intervention in individuals with NS. In the meantime, based on data generated from other population groups, a rational approach to the clinical management of hyperlipidemia in these patients is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Focal and segmental glomerulosclerosis: Analogies to atherosclerosis
Diamond, J. R., & Karnovsky, M. J. (1988) · Kidney International · doi:10.1038/ki.1988.87 · Cited by 330
FREQUENCY OF RISK FACTORS FOR ISCHÆMIC HEART-DISEASE IN A HEALTHY BRITISH POPULATION
Lewis, B., Wootton, I. D. P., Krikler, D. M., February, A., Chait, A., Oakley, C. M., Sigurdsson, G., Maurer, B., & Birkhead, J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92438-6 · Cited by 165
Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia
Saito, T., Sato, H., Kudo, K.-I., Oikawa, S.-I., Shibata, T., Hara, Y., Yoshinaga, K., & Sakaguchi, H. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80134-9 · Cited by 148
Cited by
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 672
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Strippoli, G. F. M., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C. (2008) · BMJ · doi:10.1136/bmj.39472.580984.ae · Cited by 402
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 332
Metadata
- Authors
- Wheeler, D. C., & Bernard, D. B.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 1994-03
- Volume
- 23
- Issue
- 3
- Pages
- 331-346
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2029988322
- Cited by
- 194
- References
- 3
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment. https://app.cochat.ai/papers/10.1016/s0272-6386(12)80994-2
- The paper
- Wheeler, D. C., & Bernard, D. B. (1994). Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment. American Journal of Kidney Diseases. https://doi.org/10.1016/s0272-6386(12)80994-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.